Tags

Type your tag names separated by a space and hit enter

Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11):1466-71.CE

Abstract

Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RR(current), 1.5 (95% CI, 1.0-2.4); RR(former), 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RR(current), 3.3 (95% CI, 1.6-6.9); RR(former), 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.

Authors+Show Affiliations

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA. cerhan.james@mayo.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12433728

Citation

Cerhan, James R., et al. "Hormone Replacement Therapy and Risk of Non-hodgkin Lymphoma and Chronic Lymphocytic Leukemia." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 11, 2002, pp. 1466-71.
Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1466-71.
Cerhan, J. R., Vachon, C. M., Habermann, T. M., Ansell, S. M., Witzig, T. E., Kurtin, P. J., Janney, C. A., Zheng, W., Potter, J. D., Sellers, T. A., & Folsom, A. R. (2002). Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(11), 1466-71.
Cerhan JR, et al. Hormone Replacement Therapy and Risk of Non-hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1466-71. PubMed PMID: 12433728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. AU - Cerhan,James R, AU - Vachon,Celine M, AU - Habermann,Thomas M, AU - Ansell,Steven M, AU - Witzig,Thomas E, AU - Kurtin,Paul J, AU - Janney,Carol A, AU - Zheng,Wei, AU - Potter,John D, AU - Sellers,Thomas A, AU - Folsom,Aaron R, PY - 2002/11/16/pubmed PY - 2003/3/8/medline PY - 2002/11/16/entrez SP - 1466 EP - 71 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 11 IS - 11 N2 - Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RR(current), 1.5 (95% CI, 1.0-2.4); RR(former), 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RR(current), 3.3 (95% CI, 1.6-6.9); RR(former), 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12433728/Hormone_replacement_therapy_and_risk_of_non_hodgkin_lymphoma_and_chronic_lymphocytic_leukemia_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12433728 DB - PRIME DP - Unbound Medicine ER -